H.C. Wainwright Reiterates Nuvectis Pharma (NVCT) at Buy with $14 PT, Sees 85% Probability of Success for NXP800
Tweet Send to a Friend
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $14.00 price target on Nuvectis Pharma (NASDAQ: NVCT), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
